Abelin
Alex Brett Abelin, New York, NY US
Patent application number | Description | Published |
---|---|---|
20140040626 | ANONYMIZATION AND REATTRIBUTION FRAMEWORK FOR OFFLINE IDENTIFIERS - A method for managing information may include associating at least one offline device with personal information identifying a user. An identifier paired with the at least one offline device may be mapped to the personal information to create an identity-to-device association record. At least a portion of the identity-to-device association record may be edited by the user. The at least a portion of the identity-to-device association record may include activity information associated with the identifier paired with the at least one offline device. The personal information may be owned by the user. The activity information may include information (e.g., biometric data and/or location data) about activity of the user while using the offline device. The editing may include deleting the activity information associated with the identifier paired with the at least one offline device. | 02-06-2014 |
Christophe Abelin, Le Gres FR
Patent application number | Description | Published |
---|---|---|
20120101793 | METHOD, DEVICES AND COMPUTER PROGRAM FOR ASSISTING IN THE DIAGNOSTIC OF AN AIRCRAFT SYSTEM, USING FAILURE CONDITION GRAPHS - The invention in particular has as an object aid in diagnosis of a system of an aircraft, comprising a plurality of sub-systems at least one of which comprises means for monitoring and notification of at least one detected event, using graphs of feared events. After a message of notification of occurrence of the said detected event has been received ( | 04-26-2012 |
Jennifer G. Abelin, Sommers US
Patent application number | Description | Published |
---|---|---|
20150328297 | TARGET PEPTIDES FOR COLORECTAL CANCER THERAPY AND DIAGNOSTICS - A set of target peptides are presented by HLA A*0201, B*0301, B*0702 and B*2705 on the surface of disease cells. They are envisioned to, among other things, stimulate an immune response to the proliferative disease, e.g., colorectal cancer, to function as immunotherapeutics in adoptive T cell therapy or as a vaccine, facilitate antibody recognition of tumor boundaries in surgical pathology samples, act as biomarkers for early detection and/or diagnosis of the disease, and/or act as targets in the generation antibody-like molecules which recognize the target-peptide/MHC complex. | 11-19-2015 |